Pfizer
Viagra patent expiry opens up market
June 24, 2013Manufacturing and Production, Research and Development, Sales and Marketing ED, Pfizer, generics, viagra
Pfizer lost its UK patent rights to its erectile dysfunction drug Viagra over the weekend, leading to an influx of …
Pfizer wins $2.15 billion patent case
June 13, 2013Sales and Marketing Pfizer, Takeda, Teva, protonix
Pfizer and Takeda are to split $2.15 billion in damages from two generics manufacturers as a settlement for lost sales, …
Mirna appoints ex-Pfizer senior director
June 6, 2013Manufacturing and Production, Research and Development, Sales and Marketing Pfizer, miRNA
Biotech firm Mirna Therapeutics has appointed Dr Sinil Kim as vice president of Oncology and chief medical officer. Kim will …
Pfizer, UCB sell plants to smaller drugmakers
May 30, 2013Manufacturing and Production Pfizer, UCB
This week saw two pharma companies offload US manufacturing facilities to contract manufacturing organisations (CMOs), with Pfizer selling a plant …
Pfizer abandons cancer trial
May 22, 2013Research and Development, Sales and Marketing Cancer, Inotuzumab ozogamicin, Pfizer, oncology
Pfizer’s oncology pipeline has suffered a blow with the company abandoning a Phase III study of one of its investigational …
Pfizer targets Newcastle
May 15, 2013Research and Development, Sales and Marketing ABPI, Cameron, NHS, Newcastle, Pfizer
Pfizer has earmarked Newcastle Hospitals NHS Foundation Trust as one of 60 sites worldwide to take part in a key …
New Viagra site launched
May 10, 2013Manufacturing and Production, Medical Communications, Sales and Marketing ED, Pfizer, viagra
Pfizer has launched a new sales website for Viagra, the ‘little blue pill’ which is its most counterfeited medicine, to …
Pfizer sales shrink 9 per cent
April 30, 2013Sales and Marketing Ian Read, Lipitor, Pfizer
Pfizer endured another painful cut to its revenues in the first quarter of 2013, with sales down $1.4 billion, or …
Pfizer and Merck create major diabetes alliance
April 30, 2013Research and Development, Sales and Marketing Merck, Pfizer, diabetes
Pfizer and Merck have unveiled a major new alliance in diabetes which is likely to raise the stakes in the …
Pfizer’s Xeljanz rejected in Europe
April 28, 2013Sales and Marketing CHMP, Humira, Pfizer, RA, Xeljanz, rheumatoid arthritis
Pfizer has suffered a major setback with the rejection of its new arthritis drug in Europe.The EMA’s medicines committee the …
Venaxis appoints former Pfizer executive to Board of directors
April 19, 2013Manufacturing and Production, Research and Development, Sales and Marketing Pfizer, venaxis, williams
Diganostic firm Venaxis has appointed SomaLogic’s chief medical officer Stephen Williams to the company’s Board of directors.
Big pharma appointments to PhRMA Board
April 15, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Big Pharma, Celgene, Merck, Pfizer, PhRMA
Chairman and chief executive of Celgene Robert Hugin has been elected chairman of the Pharmaceutical Research and Manufacturers of America …
Eliquis approved by NICE
February 28, 2013Sales and Marketing BMS, Eliquis, NICE, Pfizer
In a move which will cheer Bristol-Myers Squibb and Pfizer, NICE has recommended oral blood-thinner Eliquis for use on the …
Sanofi won’t follow trend for spin-offs
February 8, 2013Sales and Marketing Abbott, Pfizer, Sanofi, Viehbacher
Sanofi’s chief executive Chris Viehbacher says the firm plans to maintain its portfolio of business divisions for the foreseeable future, …
CHMP nod for Pfizer CML drug
January 21, 2013Sales and Marketing CHMP, CML, FDA, Pfizer
Pfizer’s cancer drug bosutinib has been given a positive opinion by the CHMP for patients with chronic myelogenous leukemia (CML). …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
